Listar por autor "Aelion, Jacob"
Mostrando ítems 1-2 de 2
-
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)
Edwards, Christopher J.; Blanco García, Francisco J; Crowley, Jeffrey; Birbara, Charles A.; Jaworski, Janusz; Aelion, Jacob; Stevens, Randall M.; Vessey, Adele; Zhan, Xiaojiang; Bird, Paul (BMJ, 2016-01-20)[Abstract] Objective. To evaluate apremilast treatment in patients with active psoriatic arthritis, including current skin involvement, despite prior therapy with conventional disease-modifying antirheumatic drugs and/or ... -
Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)
Nash, Peter; Ohson, Kamal; Walsh, Jessica; Delev, Nikolay; Nguyen, Dianne; Teng, Lichen; Gómez-Reino, Juan J.; Aelion, Jacob (BMJ, 2018-01-17)[Abstract] Objective Evaluate apremilast efficacy across various psoriatic arthritis (PsA) manifestations beginning at week 2 in biological-naïve patients with PsA. Methods Patients were randomised (1:1) to apremilast ...